Morphinans are a class of compounds containing the basic structure of morphine. It is wellknown that morphinans possess diverse pharmacological effects on the central nervous system. This review will demonstrate novel neuroprotective effects of several morphinans such as, dextromethorphan, its analogs and naloxone on the models of multiple neurodegenerative disease by modulating glial activation associated with the production of a host of proinflammatory and neurotoxic factors, although dextromethorphan possesses neuropsycotoxic potentials. The neuroprotective effects and the therapeutic potential for the treatment of excitotoxic and inflammatory neurodegenerative diseases, and underlying mechanism of morphinans are discussed.
INTRODUCTION
Morphinan derivatives, which include dextromethorphan (DM; 3-methoxy-17-methylmorphinan), its analogs and naloxone, belong to a chemical class related to the opiates. Accumulating evidence suggests that morphinans may play a role in neuronal modulation. DM is a common ingredient in more than 125 cough and cold remedies. Patented by Hoffmann-La Roche in 1954 as an antitussive agent, DM has strong safety and efficacy profiles with no sedative or addictive properties at the recommended doses (Bem and Peck, 1992) . A potential advantage of DM is its lack of gastrointestinal side effects, such as constipation, and it causes less central nervous system (CNS) depression than opioids when used as antitussives at usual doses. In the past decade, investigators have documented that DM has an NMDA receptor antagonistic effect with neuroprotection. However, the DM dose for the neuroprotective effect is much higher than the cough suppressant dosage. Clinically, high doses of DM can produce psychotropic effects (Wolfe and Caravati, 1995; Desai et al., 2006) . Furthermore, DM has been recognized as the object of drug-seeking behaviour in several countries (Cranston and Yoast, 1999; Chung et al., 2004) . That hampers the development of DM as a useful neuroprotective agent. We will discuss DM analogs (incuding DM metabolites) with improved safety profiles in this review.
Endogenous opioid peptides are widely distributed in the central nervous system (CNS) and are important in regulating the development of neural cells (Knapp et al., 1998) . They interact with related yet distinct G-protein coupled receptors to exert their physiological effects, including nociceptive/analgesic effects, respiration, ionic channel activity, and immune responses (Satoh and Minami, 1995; Roy and Loh, 1996) . So far, at least three types of opioid receptors (µ, δ, and κ) have been identified (Satoh and Minami, 1995) . Another morphinan, naloxone, in particular the (-)-stereoisomer, is a stereospecific yet non-selective antagonist of the three classical opioid receptors (Chien and VanWinkle, 1996) . Accumulating evidence sug- 
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gests that naloxone, which shares a basic opiate-like structure with DM, might also have neuroprotective effects in an opiate receptor-independent fashion (Chatterjie et al., 1996; Liu et al., 2002; Qin et al., 2005) . Thus, studies have demonstrated that DM and its analogs are neuroprotective against neurodegeneration or inflammtion, at least in part through a mechanism similar to that of naloxone. The present review is designed to extend earlier understanding of negative and positive effects caused by DM or DM analogs (including DM metabolites), and to discuss the neuroprotective potential of naloxone (Fig. 1) .
METABOLIC PATHWAY OF DM
DM is metabolized primarily to dextrorphan (DX) by O-demethylation, and to a lesser extent to 3-methoxymorphinan (3-MM) by N-demethylation. Both metabolites are further demethylated to 3-hydroxymorphinan (3-HM) (Fig. 2) . Urinary recovery studies in humans and rats indicate that DX and 3-HM are excreted largely (>95%) as glucuronide conjugates. The pharmacology of 3-MM is not significant, and it does not have major behavioral side effects. We have observed that 3-HM has antiparkinsonian effects with behavioral safety. The major metabolite, DX, has neuroprotective potential (Tortella et al., 1989b) . DX has a lower affinity than DM at the [ 3 H]DM binding site (Craviso and Musacchio, 1983 ), but has a higher affinity than DM at the phencyclidine (PCP) receptor (Murray and Leid, 1984) and produces PCP-like discriminative stimulus effects (Holtzman, 1980) . The extent of the metabolic conversion of DM to DX is highly dependent on the route of administration (Wu et al., 1995) . That is, considerable DX is formed when DM is administered intraperitoneally (i.p.), whereby it is absorbed into the hepatic portal circulation, while less DX may be formed when DM is administered subcutaneously (s.c.). However, Holtzman (1994) reported that DM (30 mg/kg, s.c.) has PCP-like discriminative effects of its own that are independent of conversion to DX. These are most easily appreciated in vitro when metabolism is not an important issue. In addition, ample evidence indicates that DM has effects of its own that are independent of its conversion to DX. Interestingly, DM (Holtzman, 1994) and DX (Holtzman, 1980) substituted completely for PCP in 
